Akari Therapeutics Plc
- Last sale
- Nov 12, 2026 · -10.43%
- Market cap
- $1.27T
- 186.09B shares
- Filings
- 747
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
—derivedN/M FY19 yoy
Q3 2026
Q3 2026
- $1.27T
- —
- —
- 72567.5×
- —
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Segments
Geography
LineFY2022ShareChange
United Kingdom$0.00——
United States$0.00——
Total$0.00
Pharmaceutical preparations
Akari Therapeutics Plc is the 2nd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
LLYEli Lilly & Co$65.2B44.7%31.7%$1.3T
AKTXAkari Therapeutics Plc (this company)———$1.3T
JNJJohnson & Johnson$94.2B6.0%28.5%$682.6BONCBeOne Medicines Ltd.$5.3B40.2%5.4%$617.8BABBVAbbVie Inc.$61.2B8.6%6.9%$520.5BMRKMerck & Co., Inc.$65.0B1.3%28.1%$362.3BNVSNovartis AG———$305.8BABTAbbott Laboratories$44.3B5.7%14.7%$185.8BPFEPfizer Inc$62.6B1.6%12.4%$164.3BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Akari Therapeutics Plc · CIK 1541157 · Engraved from SEC EDGAR